Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. The company focuses on developing innovative RNA-based therapies for cardiomyopathies.

Phlox Therapeutics

Phlox Therapeutics | 705 followers on LinkedIn. RNA&#39;s to rescue cardiomyopathies | Phlox Therapeutics pioneers gene therapy to alleviate and cure cardiomyopathies. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short by leveraging RNA-based strategies to reduce the negative effects caused by genetic mutations.

Cardiologist at University of Amsterdam, Medical Advisor at ARMGO Pharma and CMO at Phlox Therapeutics, advisor to Forbion

Yigal Pinto

Investment Manager at UvA AMC HvA Ventures Holding BV

Ross Gordon

Principal at BGV (BioGeneration Ventures)

Rianne Ellenbroek

Prof. Molecular Cardiology UMCU and Group leader, Hubrecht Institute KNAW

Eva van Rooij

We are very exited to announce that Phlox Therapeutics has secured 1.9M seed funding to drive forwards our mission to develop RNA therapies for rare genetic laminopathies. This round of funding will be instrumental in advancing the preclinical development of our lead program, bringing us one step closer to delivering life-changing treatments for patients with genetic cardiomyopathies. A hugh thank you to our investor syndicate, including ROM Utrecht Region , UvA - Amsterdam UMC - HvA Ventures Holding BV , Utrecht Holdings Seed Fund and FIRST fund , managed by BGV (BioGeneration Ventures) for their confidence and support in our vision. At Phlox, we are committed to pioneering innovative RNA-based approaches to address critical unmet needs in cardiovascular health. With this funding, we are energized to make substantial strides toward developing new treatment options that could transform the lives of those affected by cardiomyopathies. For more information, please see the press release: https://lnkd.in/dZSHEi8x

Exciting update from our CSO, Eva van Rooij ! Demonstrating the potential of gene therapy in treating cardiomyopathies, her research group's latest publication in Nature Cardiovascular Research highlights promising outcomes of PKP2 replacement in arrhythmogenic cardiomyopathy. Read more: https://lnkd.in/d-7XnWrV

PHLO

COM:PHLOXTHERAPEUTICS

Phlox Therapeutics

locale

market

industry

website

crunchbase

linkedin

investor of

Metrics